Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.21 +0.34 (+1.37%)

Streaming Delayed Price Updated: 1:57 PM EDT, Aug 6, 2026 Add to My Watchlist

Price and Volume

Volume	351,045
Open	24.90
Bid (Size)	25.20 (100)
Ask (Size)	25.23 (300)
Prev. Close	24.87
Today's Range	24.70 - 25.52
52wk Range	18.80 - 27.66
Shares Outstanding	44,454,792
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Today 8:00 EDT

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Q2 Earnings Call Highlights ↗

August 04, 2026

Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline...

Via MarketBeat

Performance

YTD	+3.1%	+3.1%
1 Month	-1.5%	-1.5%
3 Month	+6.4%	+6.4%
6 Month	+21.9%	+21.9%
1 Year	+11.8%	+11.8%

More News

Pacira Biosciences (NASDAQ:PCRX) Beats Q2 EPS Estimates, Misses on Revenue and Cuts Outlook ↗

August 04, 2026

Via Chartmill

Pacira BioSciences Reports Second Quarter 2026 Financial Results

August 04, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

July 28, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health ↗

June 02, 2026

Via Chartmill

PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety ↗

May 05, 2026

Via Chartmill

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

July 27, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

July 22, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 08, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

July 01, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

June 30, 2026

From Pacira BioSciences

Via GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees

May 28, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees

May 27, 2026

From Pacira BioSciences

Via GlobeNewswire

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

May 27, 2026

From Biotech Insider

Via GlobeNewswire

Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty

May 27, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy

May 26, 2026

From Pacira BioSciences

Via GlobeNewswire

A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching

May 22, 2026

From World Street Intelligence

Via GlobeNewswire

Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders

May 20, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

May 13, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

May 12, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Mails Letter to Stockholders

May 05, 2026

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release ↗

May 01, 2026

Via The Motley Fool

Pacira (PCRX) Q1 2026 Earnings Call Transcript ↗

April 30, 2026

Via The Motley Fool

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?

Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.

What exchange does Pacira BioSciences, Inc. - Common Stock trade on?

Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?

The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market

What is the current price of Pacira BioSciences, Inc. - Common Stock?

The current price of Pacira BioSciences, Inc. - Common Stock is 25.21

When was Pacira BioSciences, Inc. - Common Stock last traded?

The last trade of Pacira BioSciences, Inc. - Common Stock was at 08/06/26 01:57 PM ET

What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?

The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.12B

How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?

Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.